StockData
BioCryst Pharmaceuticals Inc logo

BioCryst Pharmaceuticals Inc (BCRX) stock

BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$7.50+0.05 (+0.67%)

Close on Nov 17, 2026Market cap $1.92BP/E –Yield –

BioCryst Pharmaceuticals gross margin

Gross margin is gross profit as a percentage of revenue.

BioCryst Pharmaceuticals's gross margin for the twelve months ending Jun 30, 2026 was 97.8%. For fiscal 2025 it was 97.8%, against 97.3% the year before. The highest annual figure on record is 100.0% in fiscal 2014.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202597.8%+0.5
FY2024Dec 31, 202497.3%−1.4
FY2023Dec 31, 202398.6%+1.0
FY2022Dec 31, 202297.6%+2.2
FY2021Dec 31, 202195.4%+4.1
FY2020Dec 31, 202091.3%−1.1
FY2019Dec 31, 201992.4%−3.1
FY2017Dec 31, 201795.5%+4.2
FY2016Dec 31, 201691.3%−5.9
FY2015Dec 31, 201597.2%−2.8
FY2014Dec 31, 2014100.0%+0.1
FY2010Dec 31, 201099.9%+6.0
FY2009Dec 31, 200993.9%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202698.2%−0.0
Q1 FY2026Mar 31, 202696.6%−0.3
Q4 FY2025Dec 31, 202597.7%+2.3
Q3 FY2025Sep 30, 202598.6%+1.4
Q2 FY2025Jun 30, 202598.3%−0.2
Q1 FY2025Mar 31, 202596.9%−1.8
Q4 FY2024Dec 31, 202495.4%−3.0
Q3 FY2024Sep 30, 202497.3%−1.5
Q2 FY2024Jun 30, 202498.4%−0.5
Q1 FY2024Mar 31, 202498.6%−0.0
Q4 FY2023Dec 31, 202398.3%+1.3
Q3 FY2023Sep 30, 202398.7%+3.4
Q2 FY2023Jun 30, 202398.9%−0.7
Q1 FY2023Mar 31, 202398.6%−0.9
Q4 FY2022Dec 31, 202297.0%−2.1
Q3 FY2022Sep 30, 202295.3%−3.2
Q2 FY2022Jun 30, 202299.6%+0.2
Q1 FY2022Mar 31, 202299.5%+30.6
Q4 FY2021Dec 31, 202199.1%−0.1
Q3 FY2021Sep 30, 202198.6%+23.4
Q2 FY2021Jun 30, 202199.4%−0.6
Q1 FY2021Mar 31, 202168.9%−31.1
Q4 FY2020Dec 31, 202099.2%+5.0
Q3 FY2020Sep 30, 202075.1%−24.9
Q2 FY2020Jun 30, 2020100.0%+0.0
Q1 FY2020Mar 31, 2020100.0%+23.8
Q4 FY2019Dec 31, 201994.1%−5.9
Q3 FY2019Sep 30, 2019100.0%+13.0
Q2 FY2019Jun 30, 2019100.0%–
Q1 FY2019Mar 31, 201976.2%–
Q4 FY2017Dec 31, 2017100.0%–
Q3 FY2017Sep 30, 201787.0%–

More BioCryst Pharmaceuticals figures

See a number that looks wrong?